Tyrosine kinase receptor indistinguishable from the c-met protein
- PMID: 2541345
- DOI: 10.1038/339155a0
Tyrosine kinase receptor indistinguishable from the c-met protein
Abstract
Growth factor receptors with protein tyrosine kinase activity are central to the control of proliferation of both normal and malignant cells. Using anti-phosphotyrosine antibodies, we have previously identified a transmembrane glycoprotein with abnormally high protein tyrosine kinase activity in a human gastric tumour cell line (GTL-16). Electrophoresis under non-reducing conditions revealed that this kinase (relative molecular mass 145,000 (145 K)) is disulphide-linked to a 50K chain in an alpha beta-complex of 190K (p190). From its novel two-chain structure, we deduced that p190 was the prototype of a new class of tyrosine kinase receptors. We now show that p190 is indistinguishable from the protein encoded by the c-met proto-oncogene and that the alpha beta-subunit structure is conserved in other human cell lines. We also show that the high level of p190 found in the GTL-16 cell line is accompanied by amplification and overexpression of c-met. This provides the first example of a functional alteration of c-met in a human tumour cell line.
Similar articles
-
c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase.Oncogene. 1991 Apr;6(4):553-9. Oncogene. 1991. PMID: 1674365
-
Biosynthesis of the protein encoded by the c-met proto-oncogene.Oncogene. 1989 Nov;4(11):1383-8. Oncogene. 1989. PMID: 2554238
-
Protein kinase-c activation inhibits tyrosine phosphorylation of the c-met protein.Oncogene. 1990 May;5(5):721-5. Oncogene. 1990. PMID: 2111905
-
Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.EXS. 1993;65:131-65. EXS. 1993. PMID: 8380735 Review.
-
Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene.Cell Mol Biol (Noisy-le-grand). 1994 Jul;40(5):597-604. Cell Mol Biol (Noisy-le-grand). 1994. PMID: 7981617 Review.
Cited by
-
Oncogene Downregulation by Mahanine Suppresses Drug-Sensitive and Drug-Resistant Lung Cancer and Inhibits Orthotopic Tumor Progression.Cancers (Basel). 2024 Oct 23;16(21):3572. doi: 10.3390/cancers16213572. Cancers (Basel). 2024. PMID: 39518013 Free PMC article.
-
Identification of immune- and oxidative stress-related signature genes as potential targets for mRNA vaccines for pancreatic cancer patients.Medicine (Baltimore). 2024 Jul 5;103(27):e38666. doi: 10.1097/MD.0000000000038666. Medicine (Baltimore). 2024. PMID: 38968513 Free PMC article.
-
MET Oncogene Targeting for Cancer Immunotherapy.Int J Mol Sci. 2024 Jun 1;25(11):6109. doi: 10.3390/ijms25116109. Int J Mol Sci. 2024. PMID: 38892318 Free PMC article. Review.
-
The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy.Pharmaceuticals (Basel). 2024 Mar 30;17(4):448. doi: 10.3390/ph17040448. Pharmaceuticals (Basel). 2024. PMID: 38675409 Free PMC article.
-
Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib.Cancers (Basel). 2024 Mar 5;16(5):1056. doi: 10.3390/cancers16051056. Cancers (Basel). 2024. PMID: 38473413 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
